avVaa World Health Care Products Announces Acquisition of Neuroskin Trademark and Granted Natural Health Canada License
August 12 2013 - 11:15AM
OTC Markets
avVaa World Health Care Products
7400 Beaufont Springs Drive, Suite 300
Richmond, VA 23225 United States
N E W S
R E L E A S E
Richmond, Virginia, August 12, 2013 ? avVaa World Health
Care
Products? (?the Company?)
(?avVaa? or ?the Company?) (Pink Sheets:
AVVH)
avVaa
World Health Care Products Inc. (www.avvaa.com) has
successfully negotiated the rights to the trademark ?Neuroskin?
with our
inventor in Germany and now own the registered trademark
?Neuroskin?. This
opens the doors not only to protect the existing avVaa line of
Neuroskin
products, it also allows development of additional products under
the brand
name Neuroskin. ?We are pleased to have negotiated the acquisition
of the Neuroskin
trademark and will continue to look for additional ways to add
value for our
shareholders?, said Jason Price, Chairman and CEO of
avVaa.
avVaa
World Health Care Products Inc. (www.avvaa.com) has
successfully completed the Natural Health Canada product
registration for
Neuroskin Psoriasis, Acne and Itch Relief. ?This will enable the
company to
sell Neuroskin products into the Canadian Drugstores, Natural
Product Health
Stores and other retailers who want a line of natural products that
treat skin
conditions that are approved under the Health Canada Natural
Products Act?,
said Jason Price, Chairman and CEO of avVaa. Presentation Kits are
presently
under development for presentation to retailers across
Canada.
About
avVaa World Health Care Products
avVaa World Health Care Products is a global
biotechnology company that
specializes in effective, all natural, therapeutic skin care
products that
improve quality of life and well being for consumers. avVaa's patented European skin
care formulas
are scientifically registered, FDA-Compliant, and were developed to
relieve and
treat the symptoms of common skin ailments, including eczema,
psoriasis and
acne. avVaa is poised
to manufacture and
market its OTC Neuroskin? line of skin care products through mass
food and drug
channels in the United
States and globally.
The Company's secondary line of equine and
pet care related products are already being distributed throughout
all of Canada. For more
information, visit: www.avvaa.com.
Jason Price Chairman & CEO
avVaa World Health Care Products
P:
1-866-864-6598
E: jason.price@avvaa.com
www.avvaa.com
Pink Sheets:
AVVH
Safe Harbor
This news release contains statements
which may constitute "forward-looking statements" within the
meaning
of the Securities Act of 1933 and the Securities Exchange Act of
1934, as
amended by the Private Securities Litigation Reform Act of
1995. Those statements
include statements regarding
the intent, belief or current expectations of avVaa World Health
Care Products,
and members of its management, as well as the assumptions on which
such
statements are based.
Prospective
investors are cautioned that any such forward-looking statements
are not
guarantees of future performance and involve risks and
uncertainties, and that
actual results may differ materially from those contemplated by
such
forward-looking statements. Important
factors currently known to management that could cause actual
results to differ
materially from those in forward-statements include fluctuation of
operating
results, the ability to compete successfully and the ability to
complete
before-mentioned transactions. The
Company undertakes no obligation to update or revise
forward-looking statements
to reflect changed assumptions, the occurrence of unanticipated
events or
changes to future operating results. Potential
risks and uncertainties include, but are not limited to, the
ability to procure,
properly price, retain, and successfully complete projects, the
availability of
technical personnel, changes in technology, and
competition.
Avvaa World Health Care ... (PK) (USOTC:AVVH)
Historical Stock Chart
From Jan 2025 to Feb 2025
Avvaa World Health Care ... (PK) (USOTC:AVVH)
Historical Stock Chart
From Feb 2024 to Feb 2025